Biotin
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Biotin: From Parenteral Nutrition Vitamin Component to Dyspepsia
One-Sentence Summary
Biotin (vitamin B7) is registered in South Africa as a component of parenteral vitamin and nutrition products. The registry data supplied does not state a formal indication. The TxGNN model predicts it may be effective for dyspepsia, but only 2 clinical trials and 7 publications were retrieved, and none tests biotin as a treatment for dyspepsia. The high model score is therefore not backed by clinical evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA registry data provided (registered products are parenteral vitamin and nutrition preparations) |
| Predicted New Indication | Dyspepsia |
| TxGNN Prediction Score | 99.43% |
| Evidence Level | L4 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 10 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, biotin is a water-soluble B vitamin that works as a cofactor for carboxylase enzymes in fatty acid, amino acid and glucose metabolism. Its role in South Africa is nutritional replacement, mostly within parenteral nutrition products. Mechanistically, a link to dyspepsia is not established.
The only loosely relevant paper is an open study of a multi-ingredient food supplement in functional dyspepsia after H. pylori treatment (PMID 25384804). That supplement cannot isolate any biotin effect. One case report describes a biotin-deficient infant who had been diagnosed with dyspepsia as a neonate and fed only an amino acid formula (PMID 15863846). This suggests dyspepsia may be a setting where deficiency occurs, not a condition that biotin treats.
The 99.43% score most likely reflects a knowledge-graph association rather than a proven therapeutic effect.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT05389813 | Phase 2/3 | Unknown | 150 | Oxycodone vs pregabalin as preemptive analgesia for postoperative pain. Not related to biotin or dyspepsia. |
| NCT03360435 | N/A | Completed | 99 | Transdermal vitamin absorption after bariatric surgery. A nutrient absorption study, not a dyspepsia treatment trial. |
Both trials were graded low relevance (C). No SANCTR or PACTR registrations were identified.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25384804 | 2014 | Open clinical study | Minerva Gastroenterol Dietol | Multi-component food supplement benefited functional dyspepsia after H. pylori treatment. A biotin effect cannot be isolated. |
| 15863846 | 2005 | Case report | J Dermatol | Biotin deficiency in an infant fed only amino acid formula, previously diagnosed with dyspepsia. |
| 25110039 | 2014 | Observational | Int J Mol Med | Stomach antral endocrine cells in irritable bowel syndrome. No biotin intervention. |
| 24891930 | 2014 | Observational | World J Gastrointest Endosc | Endocrine cells in the oxyntic mucosa in irritable bowel syndrome. No biotin intervention. |
| 11304845 | 2001 | Observational | J Clin Pathol | IL-10 in H. pylori gastritis. No biotin intervention. |
| 21695955 | 2011 | Clinical study | Eksp Klin Gastroenterol | Prebiotic and vitamin product (includes biotin) for gut microbiota disorders in patients on antibiotics. Multi-component. |
| 10354275 | 1999 | Observational | Kidney Int | Small bowel T cells in IgA nephropathy. Not relevant to biotin. |
There are no RCTs or systematic reviews. The retrieved papers are indirect and none tests biotin for dyspepsia.
South Africa Market Information
Five of the 10 registrations are shown. The registry data does not include approved indication text, manufacturer, or Essential Medicines List status.
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. U/22.1.4/200 | Soluvit novum 10ml vials | Injection | Not listed in data provided |
| Reg. No. 36/22.1/0508 | Cernevit | Infusion | Not listed in data provided |
| Reg. No. L/24/329 | Dextrose 20% in water 500ml | Infusion | Not listed in data provided |
| Exclusion under Section 36 & Section 14 | ITN neonatal TPN 150ml | TPN | Not listed in data provided |
| Exclusion under Section 36 & Section 14 | ITN baby 150ml | TPN | Not listed in data provided |
All registered forms are injectable or parenteral. No oral product appears in the data supplied, so route compatibility with a dyspepsia indication is unconfirmed.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is model-only: the retrieved trials are unrelated to biotin or dyspepsia, and the literature is indirect. No biotin-specific mechanism for dyspepsia is established, and the registered products are parenteral, which is an unlikely fit for this condition.
Two other predicted indications in the same pack have more support and are better candidates for review:
- Biotin metabolic disease (biotinidase deficiency and related disorders), L2, currently “Proceed with Guardrails”. It has a direct mechanistic fit and a Phase 1/2 open-label study (NCT03269045) whose product identity is unverified.
- Vitamin deficiency disorder, L3, currently “Research Question”.
To proceed, the following is needed:
- Any controlled clinical data of biotin alone in dyspepsia. Otherwise, deprioritise this indication.
- SAHPRA Professional Information (PI) warnings and contraindications for the registered products (currently a blocking data gap).
- Mechanism of action data from DrugBank.
- Approved indication text for the SAHPRA registrations.
- A review of the biotin metabolic disease candidate first. Guardrails there include confirming the composition of ORL-1B, restricting use to confirmed biotin-pathway disorders, and noting biotin interference with immunoassays (e.g. troponin, thyroid tests).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.